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http://dxObjective: This study assessed the impact of pulmonary hypertension (PH) on morbidity and mortality after the
most common cardiac operations and evaluated the accuracy of the Society of Thoracic Surgeons (STS) risk
model for patients with PH.
Methods: At a single center between 1994 and 2010, all adult cardiac operations performed with recorded
preoperative mean pulmonary arterial pressure (MPAP) and STS predicted mortality were reviewed. MPAP
was defined as normal (<25 mm Hg) or as mild (25-34 mm Hg), moderate (35-44 mm Hg), or severe
(45 mm Hg) PH. Multivariate analysis was performed to elucidate the contribution of PH to morbidity and
mortality.
Results: In all, 3343 patient records were reviewed. Coronary artery bypass grafting (CABG) was the most com-
mon procedure (67.5%), followed by aortic valve replacement (24.9%) and mitral valve procedures (6.3%).
Postoperative complications and mortality increased with increasing MPAP. Multivariable analysis found that
both moderate (odds ratio, 7.17; P<.001) and severe (odds ratio, 13.73; P<.001) PH were significantly asso-
ciated with increased mortality, even after accounting for STS risk. A subset analysis of isolated CABG cases
revealed markedly increased mortality for all categories of PH (mild odds ratio, 1.99; moderate odds ratio, 11.5;
severe odds ratio, 38.9; P<.001).
Conclusions: Morbidity and mortality were independently associated with PH. Observed mortality was
significantly higher than predicted by the STS model for patients with moderate and severe PH, particularly
in isolated CABG. Addition of PH to the STS risk model should be considered, or alternative tools should be
used to assess risk in these patients. (J Thorac Cardiovasc Surg 2013;146:631-7)A
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Pulmonary hypertension (PH) is defined as the presence of
elevated pulmonary arterial pressure, specifically mean pul-
monary arterial pressure (MPAP) greater than 25 mm Hg.1
In patients with acquired cardiac disease, PH is most often
due to elevated left atrial pressure.2 Long-standing high left
atrial pressure can lead to pulmonary vascular remodeling,
as evidenced by elevated pulmonary vascular resistance
(PVR) or transpulmonary gradient.2 The most effective
therapy for PH related to left-sided heart disease is correc-
tion of the underlying cardiac pathology, such as aortice Divisions of Cardiologya and Thoracic and Cardiovascular Surgery,b Uni-
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The Journal of Thoracic and Cavalve replacement (AVR) for aortic stenosis; however, PH
has long been recognized as a risk factor for morbidity
and mortality for patients undergoing cardiac surgery.
A host of perioperative factors, such as protamine, hypoxia,
hypercapnia, positive pressure ventilation, and systemic in-
flammatory response to cardiopulmonary bypass and blood
products can exacerbate underlying PH and result in
right ventricular failure, with additional morbidity and
mortality.3
The Society of Thoracic Surgeons (STS) risk model
evolved to guide surgeons and cardiologists by estimating
risk of operative mortality on the basis of multiple risk
factors, including patient demographic characteristics,
comorbidities, procedure, and clinical status. Importantly,
pulmonary arterial pressure is not one of these preopera-
tive variables, because it is infrequently measured and is
dependent on the ‘‘clinical state and volume-loading status
of the patient when the measurement is obtained.’’4 By
comparison, the EuroSCORE risk model does include
PH, defined as pulmonary arterial systolic pressure
(PASP) greater than 60 mm Hg.5 Moreover, the recently
released EuroSCORE II model further stratifies PH
into moderate (PASP 31-55 mm Hg) and severe (PASP
>55 mm Hg).6 Although the use of PASP is attractive
because it can be estimated noninvasively by echocardiog-
raphy, there can be significant differences betweenrdiovascular Surgery c Volume 146, Number 3 631
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STS ¼ Society of Thoracic Surgeons
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sive measurement.7
This study sought to assess the impact of PH in cardiac
surgery. We hypothesized that PH is associated with greater
morbidity and mortality for patients undergoing cardiac op-
erations and that the STS risk model is not valid for patients
with significant PH. We included a subset analysis of pa-
tients undergoing isolated coronary artery bypass grafting
(CABG), because the literature on PH in this most common
cardiac operation is limited. We hypothesized that PH
would be an independent risk factor for mortality for
patients undergoing CABG as well.
MATERIALS AND METHODS
Patients
The University of Virginia institutional review board approved this
study, including a waiver for individual patient consent.
A total of 11,983 adult cardiac operations were performed at the Univer-
sity of Virginia during the study period of January 1, 1994, to December 3,
2010, and were evaluated for inclusion in this study. Patient records from
our institutional STSAdult Cardiac Surgery Databasewere queried. A total
of 5241 case records reported MPAP, and 5241 cases had a calculated STS
predicted risk of mortality (PROM). A total of 3343 cases included both
MPAP and PROM, and these comprise the study population. All included
procedures represent standard surgical approaches, and standard STS vari-
able definitions were used. Patient preoperative risk was assessed by the
calculated STS PROM for each patient at the time of the operation.
MPAP was the first recorded value after placement of the pulmonary artery
catheter before incision.
Outcomes
The primary outcomes of interest included differences between ob-
served and expected mortalities for patients with varying severity of PH,
as well as risk-adjusted associations between mortality and morbidity
and degree of PH. Secondary outcomes included observed differences in
patient morbidity, mortality, and resource use. Operative mortality was de-
fined as all patient deaths occurring during hospitalization as well those
within 30 days of the date of surgery regardless of discharge status. A com-
posite outcome of major complications was used as a proxy for major mor-
bidity and included the cumulative incidence of postoperative stroke,
perioperative myocardial infarction, renal failure, prolonged mechanical
ventilation, and pneumonia. Standard STS definitions for postoperative
events and complications were used, including prolonged mechanical ven-
tilation (>24 hours), new-onset atrial fibrillation, and renal failure (increase632 The Journal of Thoracic and Cardiovascular Surgin serum creatinine level>2.0 or double the most recent preoperative
creatinine level).
Statistical Analysis
All study outcomes and data comparisons were established a priori be-
fore data collection. Descriptive, univariate statistics included either Pear-
son c2 test or Fisher’s exact test for categoric variables and either
independent sample single-factor analysis of variance for parametric data
comparisons or the Mann-Whitney U test for nonparametric data compar-
isons. Continuous variables are expressed as either mean  SD or median
with interquartile range, depending on overall variable distribution.
Multiple logistic regression analysis was used to estimate confounder-
adjusted associations between PH category and patient morbidity (major
complications) and operative mortality. Models were adjusted for patient
risk by inclusion of the STS PROM score as well as operating surgeon
and operative year. Confounder-adjusted measures of association are re-
ported as odds ratios (ORs) with 95% confidence interval (CI). Model per-
formance and the ability of the model to discriminate between dependent
outcomes (major complications and mortality) were assessed with the
area under the receiver operating characteristic curve. Predictive Analytics
SoftWare (PASW version 18.0.0; IBM Corporation, Armonk, NY) was
used for all data manipulation and statistical analyses.
RESULTS
Baseline and Operative Characteristics Stratified by
MPAP
Although ages were similar across groups, the proportion
of female patients increased with increasing MPAP
(Table 1). Risk factors, including renal failure, lung disease,
cerebrovascular disease, and New York Heart Association
class IV heart failure, were all more common with increas-
ing severity of PH (P<.001 for all). Left ventricular ejec-
tion fraction decreased with increasing MPAP (P<.001).
Interestingly, the incidence of acute myocardial infarction
did not vary with MPAP, and the incidences of angina,
left main disease, and multivessel disease decreased with
increasing MPAP.
Operative characteristics also varied considerably with
increasing MPAP. Patients with normal or mildly elevated
MPAP were more likely to undergo CABG, whereas pa-
tients with moderate or severe PH were more likely to un-
dergo valve operations. Reoperations were more common
with increasing MPAP. Accounting for these variations in
risk factors and operations, the STS PROM increased with
increasing MPAP (normal, 1.8%; mild, 2.3%; moderate,
4.6%; severe, 5.2%; P< .001). Finally, crossclamp and
CPB times were significantly longer in patients with
increasing MPAP.
Adjusted and Unadjusted Risks Rise With Increasing
MPAP
Complications occurred more frequently with increasing
MPAP (Table 2). Pneumonia, prolonged mechanical venti-
lation, and renal failure were all significantly associated
with PH, as were rare but catastrophic complications such
as cardiac arrest. The composite incidence of major compli-
cations increased significantly with higher MPAP (normal,ery c September 2013
TABLE 1. Patient risk factors and operative characteristics stratified by mean pulmonary arterial pressure
Total
MPAP (mm Hg)
P valueNormal,<25 Mild, 25-34 Moderate, 35-44 Severe,>44
N 3343 1816 1068 334 125
Age (y, mean  SD) 65.6  11.5 65.9  11.3 65.7  11.7 66.2  11.3 64.2  11.4 .306
Female (no.) 1017 (30.4%) 508 (28%) 327 (30.6%) 131 (39.2%) 51 (40.8%) <.001
MPAP (median and IQR) 20 (16-22) 28 (26-30) 39 (36-41) 50 (47-56) <.001
Preoperative comorbidities (no.)
Renal failure 306 (9.2%) 133 (7.3%) 100 (9.4%) 49 (14.7%) 24 (19.2%) <.001
Chronic lung disease 321 (9.6%) 127 (7.0%) 127 (11.9%) 43 (12.9%) 24 (19.2%) <.001
Peripheral arterial disease 511 (15.3%) 237 (13.1%) 186 (17.1%) 73 (21.9%) 18 (14.4%) <.001
Cerebrovascular disease 556 (16.6%) 268 (14.8%) 203 (19.0%) 55 (16.5%) 30 (24.0%) .003
Diabetes mellitus 1185 (35.4%) 572 (31.5%) 426 (39.9%) 135 (40.4%) 52 (41.6%) <.001
Dyslipidemia 2258 (67.5%) 1249 (68.8%) 726 (68.0%) 202 (60.5%) 81 (67.5%) .025
Family history of CAD 1727 (51.7%) 953 (52.5%) 562 (52.6%) 149 (44.6%) 63 (50.4%) .055
Hypertension 2609 (78.0%) 1403 (77.3%) 854 (80.0%) 255 (76.3%) 97 (77.6%) .318
Cardiac disease (no.)
Acute MI 1068 (32.5%) 577 (31.8%) 363 (34.0%) 107 (32.0%) 39 (31.2%) .649
Angina 1647 (49.3%) 976 (53.7%) 505 (47.3%) 123 (36.8%) 43 (34.4%) <.001
NYHA class <.001
I 359 (10.7%) 197 (10.8%) 115 (10.8%) 36 (10.8%) 11 (8.8%)
II 508 (15.2%) 321 (17.7%) 147 (13.8%) 32 (9.6%) 8 (6.4%)
III 740 (22.1%) 372 (20.5%) 258 (24.2%) 77 (23.1%) 33 (26.4%)
IV 817 (24.4%) 355 (19.5%) 274 (25.7%) 129 (38.6%) 59 (47.2%)
Atrial fibrillation (no.) 301 (9.0%) 112 (6.2%) 108 (10.1%) 58 (17.4%) 23 (18.4%) <.001
LVEF (%, median and IQR) 55% (45%-63%) 54% (40%-60%) 45% (30%-60%) 45% (30%-60%) <.001
Left main disease (no.) 924 (27.6%) 538 (29.6%) 289 (27.1%) 78 (23.4%) 19 (15.2%) .001
Diseased vessels (no.) <.001
None 488 (14.6%) 224 (12.3%) 157 (14.7%) 70 (21.0%) 37 (29.6%)
1 278 (8.3%) 134 (7.4%) 80 (7.5%) 49 (14.7%) 15 (12.0%)
2 576 (17.2%) 328 (18.1%) 181 (16.9%) 47 (14.1%) 20 (16.0%)
3 1992 (59.6%) 1129 (62.2%) 646 (60.5%) 164 (49.1%) 53 (42.4%)
Status (no.) <.001
Elective 1765 (52.8%) 986 (54.3%) 571 (53.5%) 149 (44.6%) 59 (47.2%)
Urgent 1469 (43.9%) 785 (43.2%) 463 (43.4%) 163 (48.8%) 58 (46.4%)
Emergency 102 (3.1%) 42 (2.3%) 34 (3.2%) 19 (5.7%) 7 (5.6%)
Salvage 5 (0.1%) 2 (0.1%) 0 (0%) 2 (0.6%) 1 (0.8%)
Procedure (no.) <.001
CABG 2258 (67.5%) 1367 (75.3%) 705 (66.0%) 149 (44.6%) 37 (29.6%)
Isolated AVR 833 (24.9%) 374 (20.5%) 278 (26.0%) 125 (37.4%) 56 (44.8%)
Isolated MVR 209 (6.3%) 60 (3.3%) 69 (6.5%) 52 (15.6%) 28 (22.4%)
CABG plus valve 43 (1.2%) 15 (0.8%) 16 (1.5%) 8 (2.4%) 4 (3.2%)
Reoperation (no.) 195 (5.8%) 76 (4.2%) 64 (6.0%) 39 (11.7%) 16 (12.8%) <.001
Intraoperative blood products (no.) 856 (25.6%) 375 (20.6%) 311 (29.1%) 128 (38.3%) 42 (33.6%) <.001
Crossclamp time (min, median and IQR) 69 (54-91) 73 (55-94) 79 (62-101) 80 (64-108) <.001
Cardiopulmonary bypass time
(min, median and IQR)
93 (75-118) 99 (78-125) 109 (88-139) 114 (88-149) <.001
STS predicted mortality
(%, median and IQR)
1.8 (0.8-4.1) 2.3 (1.1-5.3) 4.6 (2.3-9.0) 5.2 (2.3-11.5) <.001
AVR, Aortic valve replacement; CABG, coronary artery bypass grafting; CAD, coronary artery disease; IQR, interquartile range; LVEF, left ventricular ejection fraction; MI,
myocardial infarction; MPAP, mean pulmonary arterial pressure; NYHA, New York Heart Association; STS, Society of Thoracic Surgeons; SD, standard deviation.
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P < .001). As a consequence, hospital stay of patients
with at least moderate PH was on average 2 days longer
than that of patients without PH.The Journal of Thoracic and CaAs expected, the mortality increased significantly in pa-
tients with worsening PH (normal, 1.2%; mild, 2.1%; mod-
erate, 7.2%; severe, 12.8%; P< .001). Importantly, the
observed mortality incrementally increased beyond thatrdiovascular Surgery c Volume 146, Number 3 633
TABLE 2. Postoperative complications and mortality stratified by median pulmonary arterial pressure
Total
MPAP (mm Hg)
P valueNormal,<25 Mild, 25-34 Moderate, 35-44 Severe,>44
N 3343 1816 1068 334 125
Pneumonia 128 (3.8%) 42 (2.3%) 44 (4.1%) 29 (8.7%) 13 (10.4%) <.001
Prolonged mechanical ventilation 331 (9.9%) 115 (6.3%) 108 (10.1%) 77 (23.1%) 31 (24.8%) <.001
Stroke 81 (2.4%) 42 (2.3%) 22 (2.1%) 11 (3.3%) 6 (4.8%) .191
Renal failure 178 (5.3%) 63 (3.5%) 52 (4.9%) 45 (13.5%) 18 (14.4%) <.001
Myocardial infarction 12 (0.4%) 7 (0.4%) 3 (0.3%) 1 (0.3%) 1 (0.8%) .818
Atrial fibrillation 708 ( 21.2%) 356 (19.6%) 244 (22.8%) 79 (23.7%) 29 (23.2%) .111
Cardiac arrest 92 (2.8%) 23 (1.3%) 32 (3.0%) 25 (7.5%) 12 (9.6%) <.001
Reoperation for bleeding or tamponade 89 (2.7%) 43 (2.4%) 22 (2.1%) 16 (4.8%) 8 (6.4%) .002
Multiple organ system failure 61 (1.8%) 15 (0.8%) 12 (1.1%) 22 (6.6%) 12 (9.6%) <.001
Major complications 482 (14.4%) 189 (10.4%) 153 (14.3%) 100 (29.9%) 40 (32.0%) <.001
Any complication 1199 (35.9%) 579 (31.9%) 395 (37.0%) 164 (49.1%) 61 (48.8%) <.001
Hospital stay (postoperative d, median and IQR) 5 (4-6) 6 (5-7) 7 (5-11) 7 (5-11) <.001
Observed mortality 21 (1.2%) 22 (2.1%) 24 (7.2%) 16 (12.8%) <.001
Data are number with percentage except as specified. IQR, Interquartile range; MPAP, mean pulmonary arterial pressure.
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PH (Figure 1). Specifically, in patients with severe PH, the
actual mortality was 2.46-fold higher than the STS PROM
(P ¼ .04).
To explore this relationship further, a multivariate analy-
sis was performed to evaluate the impact of severity of PH
on mortality (Table 3). Relative to patients with normal
MPAP, moderate PH was significantly associated with mor-
tality (OR, 7.17; P<.001), even after accounting for cova-
riates such as STS PROM. Furthermore, patients with
severe PH had the greatest adjusted risk of mortality (OR,
13.73; P<.001). Multivariate analysis was also performed
to assess impact of PH on major complications (Table 3).
Even mild PH was associated with increased risk of major
complications (OR, 1.47), which increased for moderate
(OR, 3.76) and severe PH (OR, 4.24; P<.001).FIGURE 1. Observed and predicted mortalities stratified by me
634 The Journal of Thoracic and Cardiovascular SurgRisk in Isolated CABG Increases With MPAP
Because isolated CABG was the most common opera-
tion in this cohort, comprising more than 2000 patients,
we analyzed the complication rate and mortality in this
subset of patients (Table 4). Similar to the evaluation of
the entire study cohort, the incidence of postoperative
pneumonia, prolonged mechanical ventilation, and renal
failure increased with worsening PH. In fact, more than
50% of patients undergoing CABG with moderate or se-
vere PH had at least 1 complication, compared with
only 30% for the entire CABG cohort. Mortality increased
markedly with increasing MPAP (normal, 0.9%; mild,
1.7%; moderate, 8.1%; severe, 21.6%; P< .001) and to
a much greater extent than the STS PROM (normal,
1.3%; mild, 1.6%; moderate, 3.8%; severe, 1.7%;
P< .001). The ratio of observed to expected mortality isan pulmonary arterial pressure (MPAP) for the entire cohort.
ery c September 2013
TABLE 3. Multivariate analysis demonstrating significant association
between pulmonary hypertension and mortality and major
complications
Mortality Major complications
OR (95% CI) P value OR (95% CI) P value
Entire cohort
Normal (<25) 1 <.001 1 <.001
Mild (25-34) 1.74 (0.95-3.18) 1.47 (1.16-1.86)
Moderate (35-44) 7.17 (3.91-6.68) 3.76 (2.82-5.02)
Severe (>44) 13.7 (6.68-26.8) 4.24 (2.71-6.45)
Isolated CABG
Normal (<25) 1 <.001 1 <.001
Mild (25-34) 1.99 (0.88-4.52) 1.74 (1.29-2.35)
Moderate (35-44) 11.5 (4.97-26.7) 7.19 (4.82-10.7)
Severe (>44) 38.9 (13.9-109) 9.02 (4.42-18.4)
Pulmonary hypertension categories are given as mean pulmonary arterial pressures
measured in millimeters of mercury. Model discrimination for mortality (areas under
the curve): all patients, 0.76; coronary artery bypass grafting only, 0.80. Model dis-
crimination for major complications (areas under the curve): all patients, 0.68; coro-
nary artery bypass grafting only, 0.76. Covariates included mean pulmonary arterial
pressure, Society of Thoracic Surgeons predicted risk of mortality, year of operation,
and surgeon. CABG, Coronary artery bypass grafting; CI, confidence interval; OR,
odds ratio.
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cially severe PH (P< .001).
Multivariate analysis was then performed to evaluate the
impact of PH on mortality (Table 3). Even after accounting
for STS PROM, patients with moderate PH had an 11.5-fold
increased risk of death, whereas patients with severe PH had
38.9-fold increased risk of death (P<.001). Risk-adjusted
analysis of major complications also demonstrated substan-
tially increased risk with increasing severity of PH (mild
OR, 1.74; moderate OR, 7.19; severe OR, 9.02; P<.001).DISCUSSION
Accurate assessment of surgical risk is becoming increas-
ingly important as health care reform focuses attention on
quality measures. The STS risk model is widely used inTABLE 4. Subgroup analysis of complications and mortality in patients u
pulmonary arterial pressure
Total Normal,<25
N 2258 1367 (60.5%)
Pneumonia 79 (3.5%) 32 (2.3%)
Prolonged mechanical ventilation 191 (8.5%) 72 (5.3%)
Stroke 37 (1.6%) 17 (1.2%)
Renal failure 114 (5.0%) 48 (3.5%)
Myocardial infarction 0 (0%) 0 (0%)
Any complication 736 (32.6%) 388 (28.4%)
Major complications 292 (12.9%) 120 (8.8%)
Observed mortality 44 (1.9%) 12 (0.9%)
Predicted mortality (%, median and IQR) 1.3 (0.7%-3.3%
Observed to expected mortality ratio 0.69
Data are number with percentage except as specified. IQR, Interquartile range; MPAP, me
The Journal of Thoracic and Cathe United States to predict operative risk and to compare
surgical outcomes across surgeons and hospitals. Equally
important, the STS risk model is used to aid medical deci-
sion making and to counsel patients on the potential risks
of surgical interventions, particularly in light of recent ad-
vances in percutaneous therapies. Here we have demon-
strated that patients with PH have greater operative
morbidity, including pneumonia, prolonged ventilation,
and renal failure. Furthermore, even after accounting for
more risk factors, moderate and severe PH were indepen-
dently associated with mortality. Although the STS risk
model is accurate for patients with normal pulmonary arte-
rial pressures, the model significantly underestimates the
actual risk for patients with moderate and severe PH.
PH in Cardiac Surgery
PH has long been considered a risk factor for morbidity
and mortality in cardiac surgery, although the literature on
the topic is inconsistent and reveals many unanswered ques-
tions. Most studies have been small, single-center retro-
spective analyses focusing on a single operation. Studies
have used various definitions of PH. Invasive and noninva-
sive measurements of pulmonary pressures have been used
almost interchangeably. There is a surprising paucity of re-
cent literature describing the impact of PH in cardiac sur-
gery, and most studies have focused on valve disease.
Melby and colleagues8 recently reported a single-center
retrospective analysis of 1080 patients with aortic stenosis
undergoing surgical AVR.8 PH (defined as PASP35) was
independently associated with higher operative mortality.
Moreover, long-term mortality was increased in patients
with PH, particularly if PVR was elevated at the time of
surgery (>3 Wood units) or if PASP remained elevated
postoperatively. Ben-Dor and colleagues9 published a pro-
spective cohort study of 509 patients with aortic stenosis
evaluated at their center for transcatheter AVR as
part of the Placement of AoRTic TraNscathetER Valvendergoing isolated coronary artery bypass grafting stratified by mean
MPAP (mm Hg)
P valueMild, 25-34 Moderate, 35-44 Severe,>44
705 (31.2%) 149 (6.6%) 37 (1.6%)
25 (3.5%) 16 (10.7%) 6 (16.2%) <.001
62 (8.8%) 46 (30.9%) 11 (29.7%) <.001
13 (1.8%) 6 (4.0%) 1 (2.7%) .071
30 (4.3%) 27 (18.1%) 9 (24.3%) <.001
0 (0%) 0 (0%) 0 (0%) NA
248 (35.2%) 81 (54.4%) 19 (51.4%) <.001
96 (13.6%) 59 (39.6%) 17 (45.9%) <.001
12 (1.7%) 12 (8.1%) 8 (21.6%) <.001
) 1.6 (0.9%-3.8%) 3.8 (1.6%-7.7%) 1.7 (1.1%-8.2%) <.001
1.06 2.13 12.71 <.001
an pulmonary arterial pressure; NA, not applicable.
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common in patients with severe PH, as demonstrated by
elevated PVR (>3 Woods units) in 59% and elevated
transpulmonary gradient (>12 mm Hg) in 46%. As
expected, overall mortality was higher with increasing
PASP, although the authors did not stratify outcomes by
intervention (AVR, transcatheter AVR, balloon aortic
valvuloplasty, or medical management).
Ghoreishi and colleagues10 studied the impact of PH
(defined as PASP 40) on operative and long-term mortal-
ities following 873 operations for mitral regurgitation. PH
was present in 53% of patients and was associated with
higher operative and long-term mortalities. Complications
were also more common in patients with PH, including re-
nal failure requiring dialysis, sepsis, respiratory complica-
tions, and longer hospital stay.
Literature on PH in patients undergoing CABG is lim-
ited. One retrospective study of 2149 patients who under-
went CABG at 2 centers observed higher mortality and
postoperative myocardial infarction in patients with PH be-
fore CPB.11 In our study, which included 2258 CABG pro-
cedures, we found a stepwise increase in mortality and
major complications in patients with increasing severity
of PH.We did not observe an increased risk of postoperative
myocardial infarction. One of the most striking findings was
the observed mortality of 21.6% for patients undergoing
CABG with severe PH, much higher than predicted by
STS and much greater than the entire cohort. Although
the number of patients with severe PH undergoing CABG
was small, if this finding holds true, then patients undergo-
ing isolated CABG with severe PH may be at the highest
risk. A potential explanation for this differential risk be-
tween patients undergoing CABG and those undergoing
valvular surgery is the usually rapid reduction in left atrial
pressure after correction of valvular pathology, which is
less commonly seen after CABG.
Treatment of PH
During the last 2 decades, there has been a rapid growth
in the number and availability of agents to treat PH, both
acutely and long term. Pulmonary arterial hypertension re-
sulting from congenital heart disease, connective tissue dis-
eases, or idiopathic causes, has been the primary focus of
study. Continuous intravenous epoprostenol, a direct pul-
monary vasodilator, has been shown to improve exercise
tolerance and survivial.12 Bosentan, which acts by blocking
the vasoconstriction and smooth muscle proliferation ef-
fects of endothelin, also improves exercise tolerance and
delays progression of symptoms.13 Sildenafil, a phosphodi-
esterase inhibitor that induces pulmonary vasodilation by
increasing cyclic guanosine monophosphate levels, has
been shown to increase exercise tolerance.14 More recent
advances have examined the added value of combination
therapy, as well as development of agents with improved636 The Journal of Thoracic and Cardiovascular Surgside effect profiles and stability, allowing more convenient
dosing regimens.
Although the literature supporting the use of these agents
in patients with primary pulmonary arterial hypertension is
robust, less is known about their use in patients with left-
sided heart disease. Sildenafil and bosentan have been
used successfully to lower PVR preoperatively for patients
with refractory heart failure undergoing cardiac transplanta-
tion.15 Inhaled nitric oxide and epoprostenol, milrinone,
and sildenafil are now commonly used in the perioperative
management of cardiac surgical patients, although studies
describing their use have been small and focused on hemo-
dynamic rather than clinical end points.8,16-18 The
frequency of long-term residual PH after corrective cardiac
surgery and the benefit of PH agents in these patients have
not been well characterized.
Our practice in the perioperative management of patients
with PH requiring cardiac surgery has evolved through the
years. For elective or urgent cases with evidence of PH or
right ventricular dysfunction, we favor preoperative right
heart catheterization to guide optimization of volume status
and potential use of pulmonary vasodilators. Intraopera-
tively, we frequently use milrinone and inhaled epoproste-
nol, with epinephrine for right ventricular dysfunction if
needed. Postoperatively, we are cautious with fluid resusci-
tation, slowly wean milrinone, and occasionally transition
patients to oral sildenafil.
EuroSCORE Versus STS for Cardiac Surgery
Many models are available to assess operative risk for
cardiac surgery, incorporating a variety of patient and oper-
ative characteristics. PH is included in the EuroSCORE,
Parsonnet, and Tuman models, but not in other commonly
employed models, such as STS and Cleveland Clinic
calculators.4,5,19-21 Nilsson and colleagues22 compared 19
models for predicting operative mortality in 6222 cardiac
operations. The logistic EuroSCORE model was the most
accurate model in their analysis, followed by the additive
EuroSCOREmodel and the Cleveland Clinic model. Unfor-
tunately, the STS model was not included in that study. Di-
rect comparisons of the STS and EuroSCORE models have
yielded mixed results. A second study by Nilsson and col-
leagues23 found superior discriminatory power of the addi-
tive EuroSCORE model relative to the STS model in
a retrospective single-center analysis of isolated CABG op-
erations.23 Conversely, several recent studies on AVR for
aortic stenosis have found the STS model to be highly accu-
rate in high risk cases, while the EuroSCORE model
overestimates operative mortality.24,25 Unfortunately,
EuroSCORE and EuroSCORE II could not be calculated
for our cohort, because PASP and patient mobility
information were not available in our database. It is
possible that EuroSCORE II would be a more accurate
tool for patients with moderate and severe PH.ery c September 2013
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DLimitations
There are several limitations to note. This was a single-
center, retrospective analysis that included relatively few
patients with severe PH (125; 3.8%). Patients without
a measured MPAP were obviously not included, which
likely introduced some selection bias. MPAP is a dynamic
variable that is dependent on volume status, loading condi-
tions, and ischemia. We stratified patients according to the
initial MPAP after the pulmonary artery catheter was placed
and before incision. General anesthesia and fasting can
falsely lower these values. Elevated MPAP may be due to
elevated left atrial pressure, elevated PVR, or a combination
of both, and this analysis was not able to differentiate those
groups, nor do we have data on reversibility of PVR. The
time period for this study was more than 15 years, and sub-
stantial changes in the perioperative management of pa-
tients with PH occurred during these years. Finally,
because the purpose of this study was to evaluate the valid-
ity of the STS risk model in the setting of PH, we only in-
cluded procedures with a calculated STS risk score, thus
comprising a subset of all cases at our institution in the
specified time period.
CONCLUSIONS
PH is a significant risk factor for morbidity and mortality
after common cardiac operations, including CABG, valve
operations, and CABG and valve operations together. Al-
though the STS risk model performs well in the setting of
normal or mildly elevated pulmonary arterial pressures, it
severely underestimates the actual risk in patients with
moderate or severe PH. Moreover, moderate and severe
PH are independently associated with mortality even after
adjusting for STS risk. Alternative risk models should be
considered in patients with PH to assess risk adequately.
In the future, the inclusion of PH to the STS risk model
may allow more accurate assessment of actual risk and
should be considered.
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